Background: Multi-drug resistant infections are a growing worldwide health concern. There is an urgent need to produce alternative antimicrobial agents.
Objective: The study aimed to design a new hybrid antimicrobial peptide, and to evaluate its antimicrobial activity alone and in combination with traditional antibiotics.
Methods: Herein, we designed a novel hybrid peptide (BMR-1) using the primary sequences of the parent peptides Frog Esculentin-1a and Monkey Rhesus cathelicidin (RL-37). The positive net charge was increased, and other physicochemical parameters were optimized. The antimicrobial activities of BMR-1 were tested against control and multi-drug resistant gram-negative bacteria.
Results: BMR-1 adopted a bactericidal behavior with MIC values of 25-30 µM. These values reduced by over 75% upon combination with conventional antibiotics (levofloxacin, chloramphenicol, ampicillin, and rifampicin). The combination showed strong synergistic activities in most cases and particularly against multi-drug resistance P. aeruginosa and E. coli. BMR-1 showed similar potency against all tested strains regardless of their resistant mechanisms. BMR-1 exhibited no hemolytic effect on human red blood cells with the effective MIC values against the tested strains.
Conclusion: BMR-1 hybrid peptide is a promising candidate to treat resistant infectious diseases caused by gramnegative bacteria.
[http://dx.doi.org/10.1016/j.peptides.2013.10.015] [PMID: 24172540]
[http://dx.doi.org/10.1021/ac100359p] [PMID: 20373813]
[http://dx.doi.org/10.1016/j.ijantimicag.2015.03.001] [PMID: 25857949]
[http://dx.doi.org/10.1186/s12866-019-1416-8] [PMID: 30849936]
[http://dx.doi.org/10.1074/mcp.M115.054999] [PMID: 26902206]
[http://dx.doi.org/10.3389/fchem.2017.00026] [PMID: 28487853]
[http://dx.doi.org/10.1128/AAC.45.10.2695-2702.2001] [PMID: 11557457]
[http://dx.doi.org/10.1111/j.1751-7915.2008.00063.x] [PMID: 21261881]
[http://dx.doi.org/10.1146/annurev.me.18.020167.002411] [PMID: 5337537]